Literature DB >> 25770032

Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack.

Virginia J Howard1, Rikki M Tanner2, Aaron Anderson3, Marguerite R Irvin2, David A Calhoun4, Daniel T Lackland5, Suzanne Oparil4, Paul Muntner2.   

Abstract

BACKGROUND: Blood pressure control is a paramount goal in secondary stroke prevention; however, high prevalence of uncontrolled blood pressure and use of multiple antihypertensive medication classes in stroke patients suggest this goal is not being met. We determined the prevalence and factors associated with apparent treatment-resistant hypertension in persons with/without stroke or transient ischemic attack.
METHODS: Data came from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study, a national, population-based cohort of 30,239 black and white adults aged ≥45 years, enrolled 2003-2007, restricted to 11,719 participants with treated hypertension. Apparent treatment-resistant hypertension was defined as (1) uncontrolled blood pressure (systolic ≥140 mm Hg or diastolic ≥90 mm Hg) with ≥3 antihypertensive medication classes, or (2) use of ≥4 antihypertensive medication classes, regardless of blood pressure level. Poisson regression was used to calculate characteristics associated with apparent treatment-resistant hypertension.
RESULTS: Among hypertensive participants, prevalence of apparent treatment-resistant hypertension was 24.9% (422 of 1694) and 17.0% (1708 of 10,025) in individuals with and without history of stroke or transient ischemic attack, respectively. After adjustment for cardiovascular risk factors, the prevalence ratio for apparent treatment-resistant hypertension for those with versus without stroke or transient ischemic attack was 1.14 (95% confidence interval, 1.03-1.27). Among hypertensive participants with stroke or transient attack, male sex, black race, larger waist circumference, longer duration of hypertension, and reduced kidney function were associated with apparent treatment-resistant hypertension.
CONCLUSIONS: The high prevalence of apparent treatment-resistant hypertension among hypertensive persons with history of stroke or transient ischemic attack suggests the need for more individualized blood pressure monitoring and management.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Predictors; Prevalence; Resistant hypertension; Secondary prevention; Stroke; Transient ischemic attack

Mesh:

Substances:

Year:  2015        PMID: 25770032      PMCID: PMC4475646          DOI: 10.1016/j.amjmed.2015.02.008

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  38 in total

1.  Prevalence of hypertension by duration and age at exposure to the stroke belt.

Authors:  Virginia J Howard; Robert F Woolson; Brent M Egan; Joyce S Nicholas; Robert J Adams; George Howard; Daniel T Lackland
Journal:  J Am Soc Hypertens       Date:  2010 Jan-Feb

2.  Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Authors:  Marguerite R Irvin; Daichi Shimbo; Devin M Mann; Kristi Reynolds; Marie Krousel-Wood; Nita A Limdi; Daniel T Lackland; David A Calhoun; Suzanne Oparil; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

3.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

4.  Self-report of stroke, transient ischemic attack, or stroke symptoms and risk of future stroke in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Suzanne E Judd; Dawn O Kleindorfer; Leslie A McClure; J David Rhodes; George Howard; Mary Cushman; Virginia J Howard
Journal:  Stroke       Date:  2012-12-11       Impact factor: 7.914

5.  Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort.

Authors:  Sarah R Gillett; Rebekah H Boyle; Neil A Zakai; Leslie A McClure; Nancy S Jenny; Mary Cushman
Journal:  Clin Biochem       Date:  2014-08-14       Impact factor: 3.281

6.  Validity of self-reported stroke : The Tromso Study.

Authors:  T Engstad; K H Bonaa; M Viitanen
Journal:  Stroke       Date:  2000-07       Impact factor: 7.914

7.  Cardiovascular comorbidities and blood pressure control in stroke survivors.

Authors:  Manoj Kesarwani; Alejandro Perez; Victor A Lopez; Nathan D Wong; Stanley S Franklin
Journal:  J Hypertens       Date:  2009-05       Impact factor: 4.844

8.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

9.  Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis.

Authors:  Shaheen E Lakhan; Michael T Sapko
Journal:  Int Arch Med       Date:  2009-10-20

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  15 in total

1.  Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.

Authors:  Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner
Journal:  Circulation       Date:  2017-06-20       Impact factor: 29.690

2.  Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Hemal Bhatt; Christopher M Gamboa; Monika M Safford; Elsayad Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-05-30

3.  Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk.

Authors:  Eric Judd; David A Calhoun
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

4.  Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study.

Authors:  A J Shallcross; M Butler; R M Tanner; A P Bress; P Muntner; D Shimbo; G Ogedegbe; M Sims; T M Spruill
Journal:  J Hum Hypertens       Date:  2017-07       Impact factor: 3.012

5.  Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study.

Authors:  A J Shallcross; M Butler; R M Tanner; A P Bress; P Muntner; D Shimbo; G Ogedegbe; M Sims; T M Spruill
Journal:  J Hum Hypertens       Date:  2017-01-26       Impact factor: 3.012

6.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

7.  Prevalence of electrocardiographic abnormalities based on hypertension severity and blood pressure levels: the Reasons for Geographic and Racial Differences in Stroke study.

Authors:  Hemal Bhatt; Christopher M Gamboa; Monika M Safford; Elsayed Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-06-27

8.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

9.  Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease-A Report from the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Jesse Felts; Carolyn S Brecklin; Jing Chen; Paul E Drawz; Eva Lustigova; Rupal Mehta; Edgar R Miller; Stephen M Sozio; Matthew R Weir; Dawei Xie; Xue Wang; Mahboob Rahman
Journal:  Kidney360       Date:  2020-08

10.  Apparent Treatment Resistant Hypertension Among Stroke Survivors in Ghana.

Authors:  Fred Stephen Sarfo; Bruce Ovbiagele
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-10-21       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.